



Antibody Therapeutics for Immunological Diseases



January 2021

Industry leaders spearheading the way



**Sean Bohen, MD.
PhD.**
Board of directors

CEO of Olema Oncology;
Former CMO of
AstraZeneca

Previously:
Genentech
Stanford University



John Doyle
Board of directors

Former CEO of
Castlight Health.

Previously:
Achaogen
Genentech
Renovis



Judy Chou, PhD.
*President & CEO
Board of directors*

Former Global
head/SVP of Biotech
at Bayer.

Previously:
Pfizer/Medivation
Tanvex Biopharma
Genentech
Wyeth
Abbott
Harvard Medical School



Patrick Yang, PhD.
Chairman

Former EVP of
technical operations
at Juno
Therapeutics.

Previously:
Roche
Genentech
Merck & Co.



**Stephen Juelsgaard,
DVM, JD.**
Board of directors

Former EVP,
General Counsel &
chief compliance
officer at Genentech.

Previously:
Rio Grande Neurosciences
Wilson Sonsini



Corsee Sanders, PhD.
Board of directors

Member of Board
of Trustee,
Fred Hutchinson
Former EVP of
Development at
Juno Therapeutics.


Previously:
Roche
Genentech



Joe McCracken, DVM.
*Head of business
development*

Former VP &
global head of
development &
licensing
at Roche.

Previously:
Genentech
Aventis Pharma





Validated across multiple indications


Status of Pipeline projects

Product Candidate		Indication	Pre-Clinical	Phase 1	Phase 2	Phase 3
PSGL-1 Programs	Neihulizumab (AbGn-168H)	Steroid Refractory aGVHD	Filing fast-track/breakthrough designation expected in 2021; Initial strong single dose response			
		Anti-TNF and/or anti-Integrin refractory UC	Phase 2a data demonstrated durable response even at drug-free stage			
		Plaque psoriasis and Psoriatic arthritis	Proof of concept for PSGL-1 Mab MOA; Positive Phase 2a data supports development of AbGn-168H/268			
	Leiolizumab (AbGn-268)	Multiple autoimmune diseases	Demonstrated increase in potency			



Multiple Opportunities for Indication Expansion

PSGL-1 agonists: **Neihulizumab (AbGn-168H) IV**
Leiolizumab (AbGn-268) SubQ






Antibody Therapeutics for Immunological Diseases

Judy Chou, Ph.D. | President and CEO | judy.chou@altrubio.com

WWW.ALTRUBIO.COM

Headquarters: San Francisco Bay Area | **R&D Center:** Taipei, Taiwan



FORWARD-LOOKING STATEMENTS

This presentation contains forward-looking statements, including: statements about our expectations regarding the potential benefits, activity, effectiveness and safety of our product candidates; our expectations with regard to the results of our clinical studies, preclinical studies and research and development programs, including the timing and availability of data from such studies; our preclinical, clinical and regulatory development plans for our product candidates, including the timing or likelihood of regulatory filings and approvals for our product candidates; and our expectations with regard to our ability to acquire, discover and develop additional product candidates and advance such product candidates into, and successfully complete, clinical studies. These statements involve substantial known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or achievements to be materially different from the information expressed or implied by these forward-looking statements. We may not actually achieve the plans, intentions or expectations disclosed in our forward-looking statements, and you should not place undue reliance on our forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in the forward-looking statements we make. The forward-looking statements in this presentation represent our views as of the date of this presentation. We anticipate that subsequent events and developments will cause our views to change. However, while we may elect to update these forward-looking statements at some point in the future, we have no current intention of doing so except to the extent required by applicable law. You should, therefore, not rely on these forward-looking statements as representing our views as of any date subsequent to the date of this presentation. This presentation concerns product candidates that are under clinical investigation and which has not yet been approved for marketing by the U.S. Food and Drug Administration. It is currently limited by Federal law to investigational use, and no representation is made as to its safety or effectiveness for the purposes for which it is being investigated.

